Cargando…

Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis

Breast cancer (BC) is the most prevalent cancer in women. While usually detected when localized, invasive procedures are still required for diagnosis. Herein, we developed a novel ultrasensitive pipeline to detect circulating tumor DNA (ctDNA) in a series of 75 plasma samples from localized BC patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez-Rodríguez, Begoña, Alba-Bernal, Alfonso, López-López, Esperanza, Quirós-Ortega, María Elena, Carbajosa, Guillermo, Garrido-Aranda, Alicia, Álvarez, Martina, Godoy-Ortiz, Ana, Queipo-Ortuño, María Isabel, Vicioso, Luis, Díaz-Córdoba, Gema, Roldán-Díaz, María Dunia, Velasco-Suelto, Jesús, Hernando, Cristina, Bermejo, Begoña, Julve-Parreño, Ana, Lluch, Ana, Pascual, Javier, Comino-Méndez, Iñaki, Alba, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820510/
https://www.ncbi.nlm.nih.gov/pubmed/36613590
http://dx.doi.org/10.3390/ijms24010146
Descripción
Sumario:Breast cancer (BC) is the most prevalent cancer in women. While usually detected when localized, invasive procedures are still required for diagnosis. Herein, we developed a novel ultrasensitive pipeline to detect circulating tumor DNA (ctDNA) in a series of 75 plasma samples from localized BC patients prior to any medical intervention. We first performed a tumor-informed analysis to correlate the mutations found in tumor tissue and plasma. Disregarding the tumor data next, we developed an approach to detect tumor mutations in plasma. We observed a mutation concordance between the tumor and plasma of 29.50% with a sensitivity down to 0.03% in mutant variant allele frequency (VAF). We detected mutations in 33.78% of the samples, identifying eight patients with plasma-only mutations. Altogether, we determined a specificity of 86.36% and a positive predictive value of 88.46% for BC detection. We demonstrated an association between higher ctDNA median VAF and higher tumor grade, multiple plasma mutations with a likelihood of relapse and more frequent TP53 plasma mutations in hormone receptor-negative tumors. Overall, we have developed a unique ultra-sensitive sequencing workflow with a technology not previously employed in early BC, paving the way for its application in BC screening.